-
今开：--
昨收：--
-
今日区间：--
52周区间：--
-
成交量：--
成交额：--
-
市 值：--
市盈率：--
-
振幅：
每股收益：
成交量
董事会
- Chang Qing Ye
- Chang Qing Ye is currently an Independent Non-Executive Director at Hang Sang (Siu Po) International Holding Co. Ltd. since 2025, Director at HOAU Logistics Group Co. Ltd. since 2013, Independent Director at Baozun, Inc. since 2016, Independent Non-Executive Director at Ascentage Pharma Group International Co., Ltd. since 2019, Independent Non-Executive Director at FinUp Finance Technology Group (Holding) Ltd., Independent Director at Niu Technologies since 2018, Independent Non-Executive Director at Jinxin Fertility Group Ltd. since 2019, Independent Non-Executive Director at Hygeia Healthcare Holdings Co., Ltd. since 2019, Non-Executive Director at Panjing Harbourview Investment Fund since 2019, and Member of The Chinese Institute of Certified Public Accountants and Shanghai Institute of Certified Public Accountants. Former positions include Independent Non-Executive Director at Robo.ai, Inc., Chief Financial Officer & Managing Director at CITIC Private Equity Funds Management Co Ltd from 2011 to 2015, Director at Suzhou Wanlong Electric Group Co., Ltd., Independent Non-Executive Director at Luzhou Bank Co., Ltd. from 2018 to 2022, Independent Director at VNET Group, Inc. from 2022 to 2024, Partner at PricewaterhouseCoopers Zhong Tian LLP from 1993 to 2011, Auditor at Coopers & Lybrand (London) from 1993 to 1998, Partner at PricewaterhouseCoopers Consulting Ltd. from 2004 to 2011, and Auditor at Coopers & Lybrand Ciec from 1993 to 1998. Education includes an undergraduate degree from Huazhong University of Science & Technology in 1992 and an MBA from the University of Warwick in 1999.
-
- Wei Ren
- Wei Ren is currently an Independent Non-Executive Director at Ascentage Pharma Group International Co., Ltd. since 2019. Prior to this, he was a Partner at Jingtian & Gongcheng Law Firm starting from 2003. Mr. Ren completed his graduate and undergraduate degrees at Peking University in 2003.
-
- Simon Dazhong Lu
- Simon Dazhong Lu is currently an Independent Non-Executive Director at Ascentage Pharma Group International Co., Ltd. He previously worked as a Director at McGill University from 2016 to 2018. Prior to that, he was a Managing Director at CEL Partners Co. Ltd. from 2008 to 2009 and a Partner & Investment Manager at Shanghai NewMargin Ventures Investment Management Co. Ltd. from 2002 to 2007. He also worked as an Auditor at Arthur Andersen Business Consulting Co. Ltd. (Shanghai). Dr. Lu holds a doctorate degree from Nankai University, which he obtained in 2010, and an undergraduate degree from Nankai University, which he obtained in 1991.
-
- Shao Meng Wang
- Shao Meng Wang is the founder of Oncofusion Therapeutics, Inc., founded in 2012. Dr. Wang was the founder of Ascenta Therapeutics, Inc., founded in 2003, and served as Director from 2003 to 2010. Dr. Wang is the founder of Ascentage Pharma Group Corp. Ltd., founded in 2010. Dr. Wang is the founder of Jiangsu Yasheng Pharmaceutical Development Co. Ltd., founded in 2009, and holds the title of Director & Chief Scientific Officer since 2009. Dr. Wang is the founder of Ascentage Pharma Group International Co., Ltd., founded in 2009, and has been an Independent Non-Executive Director since 2017. Dr. Wang is also the founder of Medsyn Biopharma LLC.. Dr. Wang currently serves as Director at Oncopia Therapeutics, Inc., Director at Rogel Cancer Center: University of Michigan, and Director at Ascentage International Ltd. Former positions include Professor at the University of Michigan, Assistant Professor at Georgetown University in 2000, and Editor-in-Chief of the Journal of Medicinal Chemistry from 2015 to 2020. Education includes an undergraduate degree from Peking University conferred in 1986 and a doctorate from Case Western Reserve University conferred in 1982.
-
- David Sidransky
- David Sidransky founded Israel Biotech Fund in 2014, where he is working as General partner from 2014 and Champions Oncology, Inc. in 1985, where he is working as Independent Director from 2025. Dr. Sidransky also currently works at Biosight Therapeutics, Inc., as Chairman from 2013, Advaxis Immunotherapies, as Chairman, Ayala Pharmaceuticals, Inc., as Chairman from 2017, and various other companies. Dr. Sidransky also formerly worked at Tamir Biotechnology, Inc., as Chairman from 2007 to 2020, ImClone LLC, as Vice Chairman from 2004 to 2008, Old Ayala, Inc., as Chairman from 2017 to 2023, and various other companies. Dr. Sidransky received his undergraduate degree in 1981 from Brandeis University and doctorate degree from Baylor College of Medicine.
-
- Marina S. Bozilenko
- Marina S. Bozilenko is the founder of Somatogen, Inc. Current positions include President, Chief Executive Officer & Director at Biothea Pharma, Inc. since 2021, Independent Director at Talphera, Inc. since 2021, Director at Implicit Bioscience Ltd., Director at SH Parent, Inc., and Independent Non-Executive Director at Ascentage Pharma Group International Co., Ltd. starting in 2024. Former positions include President, Chief Executive Officer & Director at Allos Therapeutics, Inc. from 1994 to 2012, Chief Executive Officer & Director at Aerpio Pharmaceuticals, Inc. from 2017 to 2019, Senior Managing Director at Bear, Stearns & Co., Inc. from 2003 to 2008, Managing Director at Banc of America Securities LLC in 2003, Managing Director at Vector Securities LLC, Managing Director & Head-West Coast at Vector Securities International, Inc. from 1998 to 1999, Director at Olema Pharmaceuticals, Inc. from 2010 to 2020, Director at SynAct Pharma AB from 2021 to 2024, Principal at Kidd & Co. LLC from 2008 to 2010, MD & Senior MD-West Coast Healthcare Investment at Prudential Vector Healthcare Group from 1999 to 2000, and Strategic Advisor at William Blair & Co. LLC from 2010 to 2024. Education includes a graduate degree from The University of Chicago conferred in 1987 and an undergraduate degree from The University of Chicago conferred in 1986.
-
- Debra Yu
- Dr. Debra Yu, MD, is an Independent Non-Executive Director at Ascentage Pharma Group International Co., Ltd., an Independent Non-Executive Director at JW (Cayman) Therapeutics Co. Ltd., an Independent Director at MeiraGTx Holdings Plc, an Advisor at JDRF International, a General Manager at Shanghai Lianbio Development Co., Ltd. and a Treasurer at Institute for Advanced Study. She is on the Board of Directors at Ascentage Pharma Group International Co., Ltd., JW (Cayman) Therapeutics Co. Ltd. and MeiraGTx Holdings Plc. Dr. Yu was previously employed as an Independent Director by ARYA Sciences Acquisition Corp. V, a President & Chief Strategy Officer by LianBio, a MD & Head-Cross Border Healthcare Investment by China Renaissance Securities (US), Inc., a Managing Director by Labrador Advisors LLC, a Vice President-Strategy by WUXI APPTEC HOLDING CO, a Senior Director by Pfizer Venture Investments LLC, a General Partner by Delphi Ventures, Inc., a Consultant by McKinsey & Co., Inc., a Senior Vice President-Global Business Development by Ascendancy Healthcare, Inc., a Managing Director by Bay City Capital LLC, a Principal by Morgan Stanley Venture Partners, and a Principal by Wilkerson Group. She also served on the board at Permanente Co. and The BayHelix Group. She received her undergraduate degree from Princeton University and a doctorate degree from Harvard Medical School.
-
- Marc E. Lippman
- Marc E. Lippman was the founder of Ascenta Therapeutics, Inc. (founded in 2003) and held the title of Director from 2010 to 2011. He is also the founder of Aurora Biopharma, Inc. Dr. Lippman's current job(s) include being a Director at Alphageneron Pharmaceuticals, Inc., Radiance Biopharma, Inc., and a Professor-Oncology at Georgetown Lombardi Comprehensive Cancer Center since 2018. He is also a Member of the American Society of Clinical Oncology, Inc., the Association of American Physicians, the American Association for Cancer Research, and the American Society for Clinical Investigation. Dr. Lippman's former job(s) include being the Chairman-Department of Medicine at The University of Miami Leonard M. Miller School of Medicine from 2017 to 2018, an Independent Director at Seagen Inc. from 2000 to 2022, the Deputy Director at Sylvester Comprehensive Cancer Center from 2008 to 2017, and the Director of Lombardi Cancer Research Center from 1988 to 2001. He was also a Senior Advisor at Perseus LLC and a Professor at the University of Michigan from 2001 to 2007. Prior to that, he was the Head-Medical Breast Cancer Section at the National Cancer Institute from 1988 to 1988. Dr. Lippman is a member of the Alpha Omega Alpha Honor Medical Society. He received his doctorate degree from Yale University in 1968 and his undergraduate degree from Cornell University in 1964. Dr. Lippman is also the founder of Aurora Biopharma, Inc...
-